Elham Homaei Hadad - Thalassemia & Hemoglobinopathy Research Center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran- Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Seyed Mohammad Sadegh Pezeshki - Thalassemia & Hemoglobinopathy Research Center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran- Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Science
Saeid Shahrabi - Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan
Amal Saki Maleki - Department of Biostatistics and Epidemiology, School of Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Najmaldin Saki - Thalassemia & Hemoglobinopathy Research Center, Health research institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Introduction: Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders that may occur after one or more mutations in hematopoietic progenitor cells. In this study, we will review the co-existence of mutations (especially dual mutations) in MPNs and its effect on the prognosis of patients. Methods: To find relevant published papers, we systematically searched six major international indexing databases, namely PubMed/Medline, EmBase, Cochrane central, ISI web of science and Scopus from Feb. ۲۰۰۰ until Jan. ۲۰۲۰. We included the following keywords in the analyses: Myeloproliferative Disorders, Mutation, Co-existence of Mutations, Acute myeloid leukemia. Results: Co-existence of several mutations in MPNs is mainly associated with a poor prognosis compared with the uni-mutated MPN disorders. There are several effective factors such as sequence of mutations, incidence of mutations in one cell or different cells, mutation and MPN type. Conclusion: It seems that monitoring the status of mutations in MPNs and recognizing the co-existence of mutations (especially dual mutations) in order to determine prognosis and possibility of progression to acute form of leukemia can lead to the prediction of prognosis in MPN patients as well as establishment of better and more reliable therapeutic strategies for patients.

Myeloproliferative disorders; Co-existence of mutations; Acute myeloid leukemia; Mutations